Selecta Biosciences, Inc. SELB
Day range unavailable
52-week range unavailable
- Market cap
- 135.20M
- Revenue (ttm)
- 48.69M
- Profit margin
- -71.98%
- Shares out
- 153.43M
- Forward P/E
- -5.87
- Beta
- 0.83
- Analysts
- Buy
- Price target
- 2.80 (+217.7%)
- Earnings date
- Nov 13, 2023
2Y -2.4227 (-78.40%)
Key statistics
- Enterprise value
- 58.09M
- PEG ratio
- 0.00
- Price / sales
- 2.78
- Price / book
- 2.06
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -86.60%
- Free cash flow
- -12.44M
- Total cash
- 112.03M
- Total debt
- 34.91M
- Return on equity
- -45.21%
- Short % of float
- 7.80%
- 50-day average
- 1.10
- 200-day average
- 1.19
Analyst view
Consensus: buy
- Target (low)
- 1.00
- Target (mean)
- 2.80
- Target (high)
- 5.00
- Strong buy2
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 13, 2023
Expected Nov 13, 2023. Consensus EPS estimate -0.06.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2023 | Sep 1, 2023 | -0.07 | — | — | — |
| Aug 17, 2023 | Jun 1, 2023 | -0.09 | — | — | — |
| May 4, 2023 | Mar 1, 2023 | -0.08 | — | — | — |
| Mar 2, 2023 | Dec 1, 2022 | -0.04 | — | — | — |
| Nov 3, 2022 | Sep 1, 2022 | 0.01 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -0.03 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 17, 2023 | Mizuho | main | Buy | Buy |
| Aug 17, 2023 | SVB Leerink | down | Outperform | Market Perform |
| Aug 17, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 17, 2023 | Needham | main | Buy | Buy |
| May 7, 2023 | HC Wainwright & Co. | reit | — | Buy |
| May 4, 2023 | Needham | reit | — | Buy |
About Selecta Biosciences, Inc.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- selectabio.com
News
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity 
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis 
Selecta Biosciences Announces Merger with Cartesian Therapeutics 
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi 
Selecta Biosciences, Inc. (SELB) Reports Q2 Loss, Misses Revenue Estimates 
Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics 
Selecta Biosciences, Inc. (SELB) Q1 2023 Earnings Call Transcript 
Earnings Scheduled For May 4, 2023 
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update 
4 Hot Penny Stocks To Watch With News This Week
Your note
Sign in to keep a note on SELB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARABE TIMOTHY CRAIG | Director | Purchase | May 8, 2022 | 250,013 |
| BRUNN CARSTEN | Chief Executive Officer | Sale | Sep 24, 2023 | 783,081 |
| COX CARRIE SMITH | Director | Purchase | Jun 12, 2022 | 212,881 |
| DESILVA NISHAN M | Director | Purchase | Dec 1, 2021 | 7,000 |
| JOHNSTON LLOYD P | Chief Operating Officer | Sale | Jan 4, 2023 | 265,515 |
| KISHIMOTO TAKASHI KEI | Officer | Stock Gift | May 30, 2023 | 225,316 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Artal Group S.A. | 5.96% | 9,136,635 | 10.23M | Jun 29, 2023 |
| Blackrock Inc. | 5.14% | 7,881,105 | 8.83M | Jun 29, 2023 |
| Vanguard Group Inc | 4.63% | 7,105,657 | 7.96M | Jun 29, 2023 |
| Boxer Capital, LLC | 2.14% | 3,284,072 | 3.68M | Jun 29, 2023 |
| FMR, LLC | 1.67% | 2,561,335 | 2.87M | Jun 29, 2023 |
| Geode Capital Management, LLC | 1.54% | 2,367,278 | 2.65M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.48% | 3,799,067 | 4.25M | Jun 29, 2023 |
| iShares Russell 2000 ETF | 1.59% | 2,434,250 | 2.99M | Aug 30, 2023 |
| Fidelity Select Portfolios - Biotechnology | 1.58% | 2,421,075 | 2.98M | Aug 30, 2023 |
| Vanguard Extended Market Index Fund | 1.11% | 1,696,040 | 1.90M | Jun 29, 2023 |
| Fidelity Small Cap Index Fund | 0.66% | 1,018,181 | 1.11M | Jul 30, 2023 |
| iShares Russell 2000 Value ETF | 0.51% | 780,424 | 959.92K | Aug 30, 2023 |